Suppr超能文献

中药治疗对心力衰竭及B型利钠肽水平变化的综合影响:一项荟萃分析。

Comprehensive effects of traditional Chinese medicine treatment on heart failure and changes in B-type natriuretic peptide levels: A meta-analysis.

作者信息

Xia Li-Li, Yang Shu-Yun, Xu Jun-Yao, Chen Han-Qing, Fang Zhu-Yuan

机构信息

Hypertension Research Institute, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210004, Jiangsu Province, China.

Department of General Practice, Southeast University Affiliated Zhongda Hospital, Nanjing 210009, Jiangsu Province, China.

出版信息

World J Clin Cases. 2024 Feb 6;12(4):766-776. doi: 10.12998/wjcc.v12.i4.766.

Abstract

BACKGROUND

Heart failure (HF), a common cardiovascular condition, is characterized by significant morbidity and mortality. While traditional Chinese medicine (TCM) is often used as a complementary approach in HF management, systematic evaluations of its impact on clinical outcomes, TCM syndrome scores, and B-type natriuretic peptide (BNP) levels are lacking. This study fills this gap through a comprehensive analysis of randomized controlled trials (RCTs) focusing on TCM for HF treatment. It encompasses an assessment of methodological quality, a meta-analysis, and an evaluation of evidence quality based on established standards. The results offer crucial insights into the potential advantages and constraints of TCM in HF management.

AIM

To systematically analyze the effects of TCM on the clinical comprehensive outcomes, TCM syndrome scores, and BNP levels in patients with HF and evaluated the quality of evidence for these trials.

METHODS

RCTs on TCM for HF treatment published since the establishment of the database were searched in four Chinese and English databases, including China National Knowledge Infrastructure, Wanfang, VIP Information Chinese Science and Technology Journal, and PubMed. Methodological quality was assessed for the included studies with the Cochrane risk-of-bias assessment tool, and the meta-analysis and publication bias assessment was performed with the RevMan5.3 software. Finally, the quality of evidence was rated according to the GRADE criteria.

RESULTS

A total of 1098 RCTs were initially retrieved. After screening, 16 RCTs were finally included in our study, which were published between 2020 and 2023. These RCTs involved 1660 HF patients, including 832 in the TCM group [TCM combined with conventional Western medicine (CMW) treatment] and 828 in the CWM group (CWM treatment). The course of treatments varied from 1 wk to 3 months. TCM syndrome differentiation was analyzed in 11 of the included RCTs. In all included RCTs, outcome indicators included comprehensive clinical outcomes, TCM syndrome scores, and BNP levels. The meta-analysis results showed significant differences between the TCM and CWM groups in terms of comprehensive clinical outcomes [risk ratio = -0.54; 95% confidence interval (CI) = -0.61, -0.47; < 0.00001], TCM syndrome scores [weighted mean difference (WMD) = -142.07; 95%CI = -147.56, -136.57; < 0.00001], and BNP levels (WMD = -142.07; 95%CI = -147.56, -136.57; < 0.00001). According to the GRADE criteria, RCTs where "TCM improves clinical comprehensive outcomes" were rated as low-quality evidence, and RCTs where "TCM reduces TCM syndrome scores" or "TCM decreases BNP levels" were rated as medium-quality evidence.

CONCLUSION

TCM combined with CWM treatment effectively improves comprehensive clinical outcomes and diminishes TCM syndrome scores and BNP levels in HF patients. Given the low and medium quality of the included RCTs, the application of these results should be cautious.

摘要

背景

心力衰竭(HF)是一种常见的心血管疾病,具有较高的发病率和死亡率。虽然中药(TCM)常被用作HF管理的辅助方法,但缺乏对其对临床结局、中医证候评分和B型利钠肽(BNP)水平影响的系统评价。本研究通过对聚焦于中药治疗HF的随机对照试验(RCT)进行全面分析填补了这一空白。它包括方法学质量评估、荟萃分析以及基于既定标准的证据质量评估。结果为中药在HF管理中的潜在优势和局限性提供了关键见解。

目的

系统分析中药对HF患者临床综合结局、中医证候评分和BNP水平的影响,并评估这些试验的证据质量。

方法

在四个中英文数据库中检索自建库以来发表的关于中药治疗HF的RCT,包括中国知网、万方、维普中文科技期刊数据库和PubMed。使用Cochrane偏倚风险评估工具对纳入研究的方法学质量进行评估,并使用RevMan5.3软件进行荟萃分析和发表偏倚评估。最后,根据GRADE标准对证据质量进行评级。

结果

最初检索到1098项RCT。筛选后,最终纳入本研究的有16项RCT,发表于2020年至2023年之间。这些RCT涉及1660例HF患者,其中中药组(中药联合传统西药(CMW)治疗)832例,CMW组(CMW治疗)828例。治疗疗程从1周到3个月不等。纳入的11项RCT分析了中医证候。在所有纳入的RCT中,结局指标包括综合临床结局、中医证候评分和BNP水平。荟萃分析结果显示,中药组和CMW组在综合临床结局方面存在显著差异[风险比=-0.54;95%置信区间(CI)=-0.61,-0.47;P<0.00001],中医证候评分方面[加权均数差(WMD)=-142.07;95%CI=-147.56,-136.57;P<0.00001],以及BNP水平方面(WMD=-142.07;95%CI=-147.56,-136.57;P<0.00001)。根据GRADE标准,“中药改善临床综合结局”的RCT被评为低质量证据,“中药降低中医证候评分”或“中药降低BNP水平”的RCT被评为中等质量证据。

结论

中药联合CMW治疗可有效改善HF患者的综合临床结局,降低中医证候评分和BNP水平。鉴于纳入RCT的质量较低和中等,这些结果的应用应谨慎。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29f4/10841132/5983e14de186/WJCC-12-766-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验